The ToGA trial was the first to establish the substantial survival advantage of trastuzumab combined with chemotherapy for advanced HER2-positive GC, thereby setting the groundwork for the use of perioperative anti-HER2 therapies (59). Here, ERBB2 is linked to gastric cancer.